Advent Life Sciences LLP 4

4 · Axonics Modulation Technologies, Inc. · Filed Nov 2, 2018

Insider Transaction Report

Form 4
Period: 2018-11-02
Transactions
  • Conversion

    Common Stock

    2018-11-02+43,82243,822 total(indirect: By Advent Life Sciences LLP)
  • Conversion

    Common Stock

    2018-11-02+1,231,1781,275,000 total(indirect: By Advent Life Sciences Fund II LP)
  • Conversion

    Common Stock

    2018-11-02+14,4121,289,412 total(indirect: By Advent Life Sciences LLP)
  • Conversion

    Common Stock

    2018-11-02+404,9371,694,349 total(indirect: By Advent Life Sciences Fund II LP)
  • Conversion

    Series B-2 Preferred Stock

    2018-11-0236,5180 total(indirect: By Advent Life Sciences LLP)
    Common Stock (43,822 underlying)
  • Conversion

    Series B-2 Preferred Stock

    2018-11-021,025,9810 total(indirect: By Advent Life Sciences Fund II LP)
    Common Stock (1,231,178 underlying)
  • Conversion

    Series C Preferred Stock

    2018-11-02337,4470 total(indirect: By Advent Life Sciences Fund II LP)
    Common Stock (404,937 underlying)
  • Conversion

    Series C Preferred Stock

    2018-11-0212,0100 total(indirect: By Advent Life Sciences LLP)
    Common Stock (14,412 underlying)
Footnotes (5)
  • [F1]Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018.
  • [F2]Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series B-2 preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The B-2 preferred stock had no expiration date.
  • [F3]Securities are held by Advent Life Sciences LLP.
  • [F4]Securities are held by Advent Life Sciences Fund II LP. Advent Life Sciences LLP is the general partner of Advent Life Sciences Fund II LP.
  • [F5]Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The C preferred stock had no expiration date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION